Asthma Biologic Treatment Denied by Insurance? How to Appeal

Severe asthma affects approximately 5–10% of asthma patients and accounts for the majority of asthma-related hospitalizations, emergency visits, and deaths. Biologic therapies — including dupilumab (Dupixent), benralizumab (Fasenra), mepolizumab (Nucala), tezepelumab (Tezspire), and omalizumab (Xolair) — can dramatically reduce exacerbations and oral corticosteroid use. Yet insurance denials for these medications are among the most common and frustrating in respiratory medicine. This guide explains how to fight back.

Why Insurers Deny Asthma Biologics

Step therapy not completed — Insurers typically require documented failure of high-dose inhaled corticosteroids (ICS) plus a long-acting beta-agonist (LABA) before approving any biologic. Some plans require additional step therapy through leukotriene receptor antagonists (montelukast) or theophylline, despite these having inferior evidence.

Biomarker thresholds not met — Each biologic has different biomarker criteria:

• Nucala (mepolizumab) and Fasenra (benralizumab): blood eosinophil count ≥150–300 cells/μL depending on the insurer
• Xolair (omalizumab): IgE levels 30–700 IU/mL and confirmed allergic sensitization
• Dupixent (dupilumab): eosinophils ≥300 cells/μL OR oral corticosteroid dependency OR comorbid moderate-to-severe atopic dermatitis
• Tezspire (tezepelumab): no specific biomarker threshold required (treats all phenotypes), but insurers often still impose eosinophil criteria

"Severe asthma" not documented — Insurers require specific criteria to qualify a diagnosis as "severe" rather than "uncontrolled moderate." Documentation of uncontrolled asthma on Step 4 or 5 GINA therapy (high-dose ICS + LABA ± oral corticosteroids) is required.

Specialist requirement not met — Some plans require evaluation by an allergist or pulmonologist specializing in severe asthma before approving a biologic.

Exacerbation documentation insufficient — Insurers typically require a minimum number of severe exacerbations in the prior year (2 or more requiring oral corticosteroids, or 1 requiring hospitalization).

Clinical Frameworks Supporting Your Appeal

GINA Guidelines (2024) — The Global Initiative for Asthma recommends add-on biologic therapy for patients with severe asthma (Step 5 treatment) who remain uncontrolled despite optimized ICS/LABA therapy. The appropriate biologic is selected based on phenotype (allergic vs. eosinophilic vs. T2-high) and biomarker profile.

FDA-Approved Indications — Each biologic has specific FDA-approved indications:

• Nucala: add-on for severe eosinophilic asthma, age ≥6
• Fasenra: add-on for severe eosinophilic asthma, age ≥6
• Dupixent: moderate-to-severe eosinophilic or OCS-dependent asthma, age ≥6
• Tezspire: add-on for severe asthma, age ≥12, all phenotypes
• Xolair: moderate-to-severe persistent allergic asthma, age ≥6

Biomarker Testing Documentation — Submit laboratory results showing eosinophil count and/or IgE level with dates. For Xolair, include the skin prick test or specific IgE (RAST) results confirming allergen sensitization.

Exacerbation History — Document each exacerbation in the past 12 months: date, treatment (oral corticosteroids, emergency visit, hospitalization), duration. Include prescription records for prednisone courses and any emergency department or hospital records.

OCS Burden Documentation — Oral corticosteroid (OCS) dependency is particularly compelling for Dupixent approval. Document cumulative oral steroid doses, systemic steroid side effects (weight gain, glucose dysregulation, adrenal suppression, bone density loss), and the inability to taper steroids without asthma worsening.

Step-by-Step Appeal Strategy

Step 1: Confirm the specific biologic and its FDA-approved criteria. Submit documentation that your clinical profile matches the approved indication exactly — diagnosis, age, biomarkers, disease severity.

Step 2: Document step therapy exhaustion. List every controller medication tried: ICS (dose and inhaler), LABA, LAMA add-on, montelukast, and any oral corticosteroid courses. Include pharmacy records and duration of each trial. Note that GINA Step 4-5 treatments must be documented as optimized and maximized before biologic therapy is appropriate.

Step 3: Submit biomarker results. Include recent blood eosinophil count (ideally from a period when not on systemic steroids, which suppress eosinophils), total IgE level, and specific allergen sensitization testing. Note that eosinophil levels should ideally be measured during a stable period.

Step 4: Provide specialist documentation. A Letter of Medical Necessity from a board-certified allergist or pulmonologist carries significant weight. The letter should state: current GINA step, specific biomarker values, exacerbation count, current medications, and clinical rationale for the specific biologic chosen over alternatives.

Step 5: Address biomarker threshold disputes. If your eosinophil count is below the insurer's threshold but your physician believes biologic therapy is still appropriate (e.g., because of OCS dependency or Dupixent's broader indication), document the clinical rationale explicitly. Tezspire's FDA approval includes patients without elevated eosinophils.

Step 6: File internal appeal, then External Independent Review: Complete Guide" class="auto-link">external review. External reviewers apply FDA labeling and GINA guidelines rather than arbitrary insurer thresholds. Asthma biologic external appeals succeed frequently when biomarker documentation and specialist support are complete.

When Your Eosinophil Count Was Suppressed by Steroids

A common problem: the insurer demands a blood eosinophil count ≥300 cells/μL, but your eosinophils were measured while you were on prednisone — which suppresses eosinophil levels. Document this explicitly in your appeal. Ask your physician to note that systemic corticosteroid use at time of testing artificially suppressed eosinophil count, and request a repeat measurement during a period off oral steroids.

Fight Back With ClaimBack

Severe uncontrolled asthma is a medical emergency waiting to happen. Biologic therapy can eliminate the need for oral steroids and dramatically reduce your hospitalization risk. ClaimBack helps you compile your exacerbation history, biomarker results, and GINA documentation into a complete, clinically accurate appeal.

Start your asthma biologic appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied